Active	Status	Sponsor type	Region	Phase	Filter
4 Active 1 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Ribeiro, Reitan
innovaTV 301, NCT04697628 / 2019-001655-39: Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer	Active, not recruiting	3	502	Europe, Canada, Japan, US, RoW	tisotumab vedotin, TIVDAK, topotecan, vinorelbine, gemcitabine, irinotecan, pemetrexed	Seagen Inc., Genmab	Cervical Cancer	07/23	08/25
NCT05492123: Nivolumab-ipilimumab and Chemoradiation for Cervical Cancer	Recruiting	2	112	RoW	Nivolumab 40 mg in 4 ml Injection, Opdivo, Ipilimumab 200 MG in 40 ML Injection, Yervoy, Chemoradiation, Cisplatin-based chemoradiation	Hospital Israelita Albert Einstein, Bristol-Myers Squibb, Brava	Uterine Cervical Neoplasms	12/26	03/28
ALICE, NCT03366051: Sentinel Node Mapping in High Risk Endometrial Cancer	Recruiting	N/A	178	RoW	Sentinel Node Mapping, Lymphadenectomy	AC Camargo Cancer Center	Endometrial Cancer, Lymph Node Metastases	12/24	12/24
Jardim, Allex
NCT05492123: Nivolumab-ipilimumab and Chemoradiation for Cervical Cancer	Recruiting	2	112	RoW	Nivolumab 40 mg in 4 ml Injection, Opdivo, Ipilimumab 200 MG in 40 ML Injection, Yervoy, Chemoradiation, Cisplatin-based chemoradiation	Hospital Israelita Albert Einstein, Bristol-Myers Squibb, Brava	Uterine Cervical Neoplasms	12/26	03/28